Aptose Biosciences Stock News

Aptose Biosciences (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, announced its financ

Aptose Biosciences Inc. (NASDAQ:APTO ) Q4 2022 Earnings Conference Call March 23, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director William Rice - Chairman, President and CEO

SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing

SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inh

SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inh

SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase in

SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhi

Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares rose 104% to $7.00 in pre-market trading. Aptevo Therapeutics said 100% clinical benefit rate was achieved in Phase 1b trial evaluating Apvo436

SAN DIEGO and TORONTO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing

SAN DIEGO and TORONTO and NEW ORLEANS, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today provided a clinical update of its lead oral myeloid kin

Data to be presented in poster at ASH Annual Meeting Data to be presented in poster at ASH Annual Meeting

SAN DIEGO and TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targe

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry. Acutus

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60. Virax Biolabs Group Limited (NASDAQ: VRAX) surged 34% to $2.25 after the company announced the distribution of a RSV-I

Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation